[HTML][HTML] Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts

Y Komano, T Nanki, K Hayashida, K Taniguchi… - Arthritis research & …, 2006 - Springer
Increased bone resorption mediated by osteoclasts causes various diseases such as
osteoporosis and bone erosion in rheumatoid arthritis (RA). Osteoclasts are derived from the …

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese …

Y Komano, M Tanaka, T Nanki, R Koike… - The Journal of …, 2011 - jrheum.org
Objective. To compare tumor necrosis factor-α (TNF-α) inhibitors to nonbiological disease-modifying
antirheumatic drugs (DMARD) for the risk of serious infection in Japanese patients …

Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: A retrospective review and case–control study of 21 patients

Y Komano, M Harigai, R Koike… - Arthritis Care & …, 2009 - Wiley Online Library
Objective To establish proper management of Pneumocystis jiroveci pneumonia (PCP) in
rheumatoid arthritis (RA) patients treated with infliximab. PCP has been observed in 0.4% of …

[HTML][HTML] Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis

T Nanki, K Takada, Y Komano, T Morio… - Arthritis research & …, 2009 - Springer
Introduction Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been
reported, and it has been thought that these cells might contribute to the pathogenesis of RA by …

Time‐dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis

R Sakai, Y Komano, M Tanaka, T Nanki… - Arthritis care & …, 2012 - Wiley Online Library
Objective To investigate associations between continuous treatments with tumor necrosis
factor (TNF) antagonists and risk for developing serious infections (SIs) over 3 years in …

Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: a nationwide …

…, M Tanaka, K Watanabe-Imai, Y Komano… - Modern …, 2016 - academic.oup.com
Objectives: To investigate and compare the risk for malignancy in rheumatoid arthritis (RA)
patients treated with biologics in Japan to the general population. Methods: Data for 14,440 …

Arthritic joint-targeting small interfering RNA-encapsulated liposome: implication for treatment strategy for rheumatoid arthritis

Y Komano, N Yagi, I Onoue, K Kaneko… - … of Pharmacology and …, 2012 - ASPET
RNA interference, mediated by small interfering RNA (siRNA), is effective in silencing genes
with a high degree of specificity. To explore the therapeutic potential of systemically …

Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk …

M Tanaka, R Sakai, R Koike, Y Komano… - Modern …, 2012 - Taylor & Francis
Objectives The association of anti-tumor necrosis factor therapy with opportunistic infections
in rheumatoid arthritis (RA) patients has been reported. The goal of this study was to clarify …

Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis

…, T Nanki, H Kohsaka, M Harigai, Y Komano… - Modern …, 2007 - Taylor & Francis
The recent widespread employing of potent biologic agents targeting tumor necrosis factor (TNF)
for the therapy of rheumatoid arthritis (RA) raises the question as to whether patients …

Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and …

…, H Sugiyama, M Tanaka, Y Komano… - Modern …, 2013 - academic.oup.com
Objectives To investigate the clinical characteristics and risk factors of Pneumocystis jirovecii
pneumonia (PCP) in rheumatoid arthritis (RA) patients treated with adalimumab. Methods …